Shore Capital is delighted to have acted as Sole Bookrunner and Broker to Poolbeg Pharma plc on its oversubscribed placing and subscription, which was upsized due to strong investor demand, raising gross proceeds of approximately £4.715m.

Poolbeg Pharma is a clinical-stage biopharmaceutical company targeting substantial markets with unmet medical needs, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and obesity treatment through its proprietary oral encapsulated GLP-1 technology.

The funds raised will enable Poolbeg to advance its lead product, POLB 001, through a Phase 2a trial and support the development of its oral GLP-1 proof-of-concept trial, whilst significantly extending the Company’s financial runway into 2027.

The Shore Capital team for Poolbeg Pharma plc:

• Corporate Advisory: David Coaten, Harry Davies-Ball
• Corporate Broking: Malachy McEntyre, Isobel Jones
• Sales champion: Andrew Kieth (with help from the Small Cap Team)
• Investor Relations: Lisa Mason (with help from Julia Barnes)